Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients

Figures & data

Table 1. Details of the demographic features of the patients and the levels of severity of the disease.

		Ficat stage			Sex (n)
Patients (n)	Age (years)	I	II	III	Male	Female
23	54.2 ± 10.1	1	7	15	12	11
Etiology
FHN Ficat stage (n)		PT-FHN Ficat stage (n)			PS-FHN Ficat stage (n)	OABN Ficat stage (n)
II	III	I	II	III	III	III
6	9	1	1	1	3	2

PTFHN: post-traumatic femoral head necrosis; PSTFHN: post steroid therapy femoral head necrosis; FCN: femoral condyles necrosis; OABN: other aseptic bone necrosis.

Table 2. MRI-evidenced improvement after HBOT in patients with ANFH.

	Total patients (n)	Improvement after HBO treatment	Aggravation after HBO treatment	Unchanged	Improvement in VAS pain score	Aggravation in VAS pain score
Ficat I	1	1	0	0	1	0
Ficat II	7	7	0	0	7	0
Ficat III	11	2	3	6	3	4

HBO: hyperbaric oxygenation.

Figure 1. Effects of HBOT on serum OPG levels in ANFH patients. HBO therapy significantly increased OPG serum concentrations throughout the whole experiment. OPG concentrations were 5.61 ± 1.99 pmol/L, 7.90 ± 1.90 pmol/L, 8.97 ± 2.07 pmol/L (p < .01), 8.99 ± 1.46 pmol/L (p < .01), and 8.18 ± 1.31 pmol/L (p < .05) at T0, T1, T2, T3, and T4, respectively. T0: Baseline, T1: after 12 HBO, T2: after 30 HBO, T3: after 45 HBO, and T4: after 60 HBO. *p < .05; **p < .01

Figure 2. Effect of HBOT on serum RANKL level in ANFH patients. There was no significant change in serum RANK-L levels during HBO treatment, being 318.2 ± 48.66 pmol/L, 347.7 ± 155.40 pmol/L, 299.7 ± 44.36 pmol/L, 303.2 ± 45.89 pmol/L, and 380.5 ± 51.41 pmol/L at T0, T1, T2, T3, and T4, respectively. T0: Baseline, T1: after 12 HBO, T2: after 30 HBO, T3: after 45 HBO, and T4: after 60 HBO.